Gt Biopharma Stock In The News
| GTBP Stock | USD 2.80 0.24 7.89% |
Our overall analysis of GT Biopharma's news coverage and content from conventional and social sources shows investors' bearish mood towards GT Biopharma. The specific impact of GT Biopharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of GT Biopharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using GT Biopharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out GT Biopharma Backtesting and GT Biopharma Hype Analysis. To learn how to invest in GTBP Stock, please use our How to Invest in GT Biopharma guide.
GTBP |
GT Biopharma Today Top News and Investor Outlook
GT Biopharma Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide GTBP and other traded companies coverage with news coverage. We help investors stay connected with GTBP headlines for the 11th of December 2024 to make an informed investment decision based on correlating the impacts of news items on GTBP Stock performance. Please note that trading solely based on the GT Biopharma hype is not for everyone as timely availability and quick action are needed to avoid losses.
GT Biopharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the GTBP earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about GT Biopharma that are available to investors today. That information is available publicly through GTBP media outlets and privately through word of mouth or via GTBP internal channels. However, regardless of the origin, that massive amount of GTBP data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of GT Biopharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of GT Biopharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to GT Biopharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive GT Biopharma alpha.
GTBP Largest EPS Surprises
Earnings surprises can significantly impact GT Biopharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-01 | 2023-09-30 | -0.1 | -0.06 | 0.04 | 40 | ||
2023-08-07 | 2023-06-30 | -0.1 | -0.05 | 0.05 | 50 | ||
2022-08-11 | 2022-06-30 | -0.17 | -0.1 | 0.07 | 41 | ||
2022-10-31 | 2022-09-30 | -0.11 | -0.22 | -0.11 | 100 | ||
2023-05-15 | 2023-03-31 | -0.14 | -0.01 | 0.13 | 92 | ||
2022-05-16 | 2022-03-31 | -0.31 | -0.17 | 0.14 | 45 |
GT Biopharma Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to GT Biopharma Stock. Current markets are slightly bearish. About 51% of major world exchanges and indexes are down. See today's market update for more information.
3rd of December 2024
GT Biopharma Stock Rating Upgraded by Roth Capital at thelincolnianonline.com
27th of November 2024
GT Biopharma faces Nasdaq delisting over equity shortfall - Investing.com at news.google.com
14th of November 2024
GT Biopharma Reports Third Quarter 2024 Financial Results - GlobeNewswire at news.google.com
13th of November 2024
Acquisition by Berk Gregory of 278058 shares of GT Biopharma subject to Rule 16b-3 at Berk Gregory
31st of October 2024
Acquisition by Berk Gregory of 50000 shares of GT Biopharma at 6.33 subject to Rule 16b-3 at Berk Gregory
25th of October 2024
Disposition of 12447 shares by Bristol Investment Fund Ltd of GT Biopharma at 1.25 subject... at Bristol Investment Fund Ltd
17th of October 2024
Acquisition by Urban Alan Louis of 23335 shares of GT Biopharma at 2.11 subject to Rule 16... at Urban Alan Louis
26th of September 2024
GT Biopharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference at globenewswire.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards GT Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, GT Biopharma's short interest history, or implied volatility extrapolated from GT Biopharma options trading.
Additional Tools for GTBP Stock Analysis
When running GT Biopharma's price analysis, check to measure GT Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GT Biopharma is operating at the current time. Most of GT Biopharma's value examination focuses on studying past and present price action to predict the probability of GT Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GT Biopharma's price. Additionally, you may evaluate how the addition of GT Biopharma to your portfolios can decrease your overall portfolio volatility.